Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at how the body processes a drug called cilofexor in people with different levels of liver impairment. A total of 57 people were enrolled across five groups: 10 with mild liver impairment, 10 with moderate liver impairment, 10 with severe liver impairment, and comparison groups of people with normal liver function (17 in one group and 10 in another). All but one participant completed the trial — that one person was in the normal liver function comparison group for cohorts 1 and 2. The reported data shows that the trial measured how much of the drug entered the bloodstream and how quickly, using several standard drug-tracking measures. One key measure was how much drug was present in the blood over time (referred to as "AUC," or area under the curve — essentially a running total of drug exposure). The reported numbers show that people with mild liver impairment had a total drug exposure (AUClast) of around 5,382 units, compared to roughly 2,973 units in their matched healthy comparison group. For moderate liver impairment, the figure was around 8,224 units versus 2,757 units in the healthy comparison group. For severe liver impairment, it was around 6,534 units versus 960 units in that group's healthy comparators. The reported peak drug level in the blood (the highest concentration reached) was 994 ng/mL for the mild impairment group, 909 ng/mL for moderate, and 427 ng/mL for severe, compared to 604, 496, and 182 ng/mL respectively in each matched healthy group. The time it took to reach that peak level ranged from about 3 to 5 hours across all groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Non-Alcoholic Fatty Liver Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You may be eligible if you have mildly reduced liver function or normal liver function (Cohort 1).
- If you have mild liver problems, your liver condition must have been measured as "mild" using a standard scoring system, and your condition must not have gotten worse in the 2 months before or during the initial check-up period (Cohort 1).
- You may be eligible if you have moderately reduced liver function or normal liver function (Cohort 2).
- If you have moderate liver problems, your liver condition must have been measured as "moderate" using a standard scoring system, and your condition must not have gotten worse in the 2 months before or during the initial check-up period (Cohort 2).
- You may be eligible if you have severely reduced liver function or normal liver function (Cohort 3).
- If you have severe liver problems, your liver condition must have been measured as "severe" using a standard scoring system, and your condition must not have gotten worse in the 2 months before or during the initial check-up period (Cohort 3).
Who may not be able to join:
- People whose liver condition has been getting worse in the 2 months before or during the screening period may not be eligible.
- There may be additional requirements or restrictions not listed here that could affect your eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pharmacokinetic (PK) Parameter: AUClast of Cilofexor; PK Parameter: AUCinf of Cilofexor; PK Parameter: Cmax of Cilofexor; PK Parameter: %AUCexp of Cilofexor; PK Parameter: Clast of Cilofexor; PK Parameter: Tmax of Cilofexor; PK Parameter: Tlast of Cilofexor; PK Parameter: λz of Cilofexor; PK Parameter: CL/F of Cilofexor; PK Parameter: Vz/F of Cilofexor; PK Parameter: t1/2 of Cilofexor
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.